Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
11-14 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Not Confirmed
Not Confirmed
12-17 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
11-14 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Industry Trade Show
Not Confirmed
12-17 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-are-building-capabilities-to-stay-ahead-of-the-curve-and-align-with-future-needs-of-global-healthcare
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india
11 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-oncology-announces-closing-of-9-0-million-registered-direct-offering-and-concurrent-private-placement-302552985.html
23 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-oncology-deploys-ai-platform-to-amplify-the-performance-of-its-commercial-team-ahead-of-lymphir-launch-302536464.html
12 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2025-financial-results-and-provides-business-update-302528078.html
17 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-oncology-announces-closing-of-9-0-million-public-offering-302508074.html
09 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302499666.html
12 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-closing-of-registered-direct-offering-of-up-to-15-8-million-priced-at-the-market-under-nasdaq-rules-302479933.html
Details:
The Company currently intends to use the net proceeds to support the commercial launch of Lymphir, a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Lead Product(s): Denileukin Diftitox,Inapplicable
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Approved FDFProduct Type: Protein
Sponsor: H.C. Wainwright & Co
Deal Size: $15.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 12, 2025
Lead Product(s) : Denileukin Diftitox,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $15.8 million
Deal Type : Public Offering
Citius Closes $15.8M Direct Offering Priced At-the-Market Under Nasdaq Rules
Details : The Company currently intends to use the net proceeds to support the commercial launch of Lymphir, a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
June 12, 2025
Details:
The Company currently intends to use the net proceeds to support the commercial launch of Lymphir, a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Lead Product(s): Denileukin Diftitox,Inapplicable
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Approved FDFProduct Type: Protein
Sponsor: H.C. Wainwright & Co
Deal Size: $15.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 10, 2025
Lead Product(s) : Denileukin Diftitox,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $15.8 million
Deal Type : Public Offering
Citius Announces a Registered Direct Offering of Up To $15.8 Million
Details : The Company currently intends to use the net proceeds to support the commercial launch of Lymphir, a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
June 10, 2025
Details:
The Company currently intends to use the net proceeds from the offering to support the commercial launch of Lymphir (denileukin diftitox) for the treatment of cutaneous T-cell lymphoma.
Lead Product(s): Denileukin Diftitox,Inapplicable
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Approved FDFProduct Type: Protein
Sponsor: H.C. Wainwright & Co
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2025
Lead Product(s) : Denileukin Diftitox,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $2.0 million
Deal Type : Public Offering
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
Details : The Company currently intends to use the net proceeds from the offering to support the commercial launch of Lymphir (denileukin diftitox) for the treatment of cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
April 01, 2025
Details:
The Company intends to use the proceeds for pre-clinical and clinical development of its product candidates, including stem cell therapy for the treatment of ARDS.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 08, 2025
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Citius Pharmaceuticals Announces $3 Million Offering Priced Under Nasdaq Rules
Details : The Company intends to use the proceeds for pre-clinical and clinical development of its product candidates, including stem cell therapy for the treatment of ARDS.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 08, 2025
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 25, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Holds FDA Type C Meeting On Phase 3 Mino-Lok® Pathway for Approval
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Product Name : Mino-Lok
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2024
Details:
The Company will use the proceeds for pre-clinical and clinical development of its product candidates, including Lymphir (denileukin diftitox) in combination of Keytruda for recurrent solid tumors.
Lead Product(s): Denileukin Diftitox,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 18, 2024
Lead Product(s) : Denileukin Diftitox,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
Details : The Company will use the proceeds for pre-clinical and clinical development of its product candidates, including Lymphir (denileukin diftitox) in combination of Keytruda for recurrent solid tumors.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
November 18, 2024
Details:
The Company will use the proceeds for pre-clinical and clinical development of its product candidates, including Lymphir (denileukin diftitox) in combination of Keytruda for recurrent solid tumors.
Lead Product(s): Denileukin Diftitox,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 15, 2024
Lead Product(s) : Denileukin Diftitox,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Private Placement
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
Details : The Company will use the proceeds for pre-clinical and clinical development of its product candidates, including Lymphir (denileukin diftitox) in combination of Keytruda for recurrent solid tumors.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
November 15, 2024
Details:
Keytruda (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777, an IL-2R binder) is being investigated in patients with recurrent solid tumors.
Lead Product(s): Denileukin Diftitox,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 11, 2024
Lead Product(s) : Denileukin Diftitox,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Pharmaceuticals Announces Phase I Pembrolizumab & LYMPHIR Trial
Details : Keytruda (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777, an IL-2R binder) is being investigated in patients with recurrent solid tumors.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Inapplicable
November 11, 2024
Details:
Lymphir (denileukin diftitox) is a recombinant fusion protein that combines the IL-2R binding domain with diphtheria toxin fragments, approved for adults with R/R cutaneous T-cell lymphoma.
Lead Product(s): Denileukin Diftitox,Inapplicable
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2024
Lead Product(s) : Denileukin Diftitox,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Gains FDA Approval for LYMPHIR Immunotherapy to Treat Cutaneous T-Cell Lymphoma
Details : Lymphir (denileukin diftitox) is a recombinant fusion protein that combines the IL-2R binding domain with diphtheria toxin fragments, approved for adults with R/R cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Inapplicable
August 09, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 21, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Pharma Hits Key Goals in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Product Name : Mino-Lok
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024
ABOUT THIS PAGE